Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Research And Development Expense of $61.12 million for the year ending 2025.
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -27.7% in Research And Development Expense from 2024 to 2025.
- This data is from LEXICON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $20.24 million | Q3 2010: $18.94 million | Q1 2011: $23.92 million | Q2 2011: $20.15 million | Q3 2011: $19.66 million | Q1 2012: $23.04 million | Q2 2012: $19.36 million | Q3 2012: $19.19 million | Q1 2013: $20.33 million | Q2 2013: $23.69 million | Q3 2013: $25.40 million | Q1 2014: $23.95 million | Q2 2014: $21.19 million | Q3 2014: $24.11 million | Q1 2015: $20.87 million | Q2 2015: $20.77 million | Q3 2015: $23.11 million | Q1 2016: $37.00 million | Q2 2016: $48.22 million | Q3 2016: $52.53 million | Q1 2017: $43.58 million | Q2 2017: $26.93 million | Q3 2017: $39.14 million | Q1 2018: $47.70 million | Q2 2018: $26.48 million | Q3 2018: $13.76 million | Q1 2019: $12.02 million | Q2 2019: $12.64 million | Q3 2019: $26.66 million | Q1 2020: $55.18 million | Q2 2020: $57.30 million | Q3 2020: $40.15 million | Q1 2021: $12.61 million | Q2 2021: $10.26 million | Q3 2021: $15.68 million | Q1 2022: $14.93 million | Q2 2022: $13.36 million | Q3 2022: $10.56 million | Q1 2023: $12.03 million | Q2 2023: $14.54 million | Q3 2023: $17.56 million | Q1 2024: $14.37 million | Q2 2024: $17.64 million | Q3 2024: $25.78 million | Q1 2025: $15.30 million | Q2 2025: $15.75 million | Q3 2025: $18.76 million.
- Over the full 17 years of available data (2009 to 2025), LEXICON PHARMACEUTICALS, INC.'s Research And Development Expense has declined by 24.8%.
- Historical annual values: Fiscal year 2025: $61.12 million | Fiscal year 2024: $84.48 million | Fiscal year 2023: $58.89 million | Fiscal year 2022: $52.82 million | Fiscal year 2021: $55.05 million | Fiscal year 2020: $153.62 million | Fiscal year 2019: $91.92 million | Fiscal year 2018: $100.24 million | Fiscal year 2017: $152.22 million | Fiscal year 2016: $163.97 million | Fiscal year 2015: $95.19 million | Fiscal year 2014: $89.28 million | Fiscal year 2013: $89.68 million | Fiscal year 2012: $82.57 million | Fiscal year 2011: $91.83 million | Fiscal year 2010: $78.52 million | Fiscal year 2009: $81.24 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: